Profile data is unavailable for this security.
About the company
Tibet Weixinkang Medicine Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical medicines and related active pharmaceutical ingredients (APIs). The Company's main products include injection of complex vitamins, injection of potassium aspartate magnesium, sucrose iron injection and potassium aspartate injection. The Company is also engaged in the production and sales of liver protection drugs and antibiotics products. The Company mainly distributes its products in the domestic market.
- Revenue in CNY (TTM)1.29bn
- Net income in CNY248.69m
- Incorporated2006
- Employees701.00
- LocationTibet Weixinkang Medicine Co Ltd3F, Block 4, Industry Center, No. 5Yuanqu South Road, Zone B, Lasa EconomicLASA 850000ChinaCHN
- Phone+86 8 916601760
- Fax+86 8 916601760
- Websitehttp://www.wxkpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lionco Pharmaceutical Group Co Ltd | 200.39m | -144.55m | 3.22bn | 475.00 | -- | 3.50 | -- | 16.05 | -0.2071 | -0.2071 | 0.2826 | 1.27 | 0.1182 | 1.86 | 2.52 | 421,872.40 | -8.52 | 0.7396 | -9.94 | 0.9562 | 42.74 | 80.88 | -72.13 | 2.08 | 6.19 | -5.98 | 0.3512 | 521.93 | -31.95 | -34.79 | 22.65 | -- | -33.18 | -- |
| Shanghai OPM Biosciences Co Ltd | 254.91m | 49.43m | 3.28bn | 285.00 | 66.44 | 1.52 | -- | 12.87 | 0.4303 | 0.4303 | 2.22 | 18.80 | 0.1095 | 2.07 | 2.54 | 894,431.90 | 2.09 | 4.34 | 2.16 | 4.65 | 58.86 | 58.31 | 19.06 | 23.40 | 19.91 | -- | 0.0315 | 45.38 | -17.41 | 48.34 | -48.72 | -- | 6.09 | -- |
| Tibet Weixinkang Medicine Co Ltd | 1.29bn | 248.69m | 3.45bn | 701.00 | 13.88 | 2.40 | -- | 2.67 | 0.5715 | 0.5715 | 2.96 | 3.30 | 0.7114 | 18.19 | 5.88 | 1,840,383.00 | 13.71 | 8.20 | 17.78 | 11.13 | 50.81 | 50.20 | 19.28 | 11.53 | 3.10 | -- | 0.0045 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
| Shanghai New World Co Ltd | 1.15bn | 33.59m | 3.63bn | 1.20k | 108.05 | 0.8633 | -- | 3.17 | 0.0519 | 0.0519 | 1.77 | 6.50 | 0.2026 | 4.62 | 7.42 | 951,798.10 | 0.5858 | 0.5242 | 0.78 | 0.7249 | 38.56 | 33.70 | 2.89 | 2.71 | 1.52 | -- | 0.1222 | 82.75 | 33.39 | -16.40 | 160.85 | -35.00 | 53.61 | -25.42 |
| Chengdu Olymvax Biopharmaceuticals Inc | 500.05m | -12.30m | 3.71bn | 471.00 | -- | 4.14 | -- | 7.41 | -0.0303 | -0.0303 | 1.23 | 2.21 | 0.3338 | 0.4197 | 1.08 | 1,061,669.00 | -1.22 | 3.17 | -1.70 | 4.68 | 93.29 | 93.00 | -3.64 | 7.44 | 1.92 | -3.90 | 0.2505 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
| Beijing Konruns Pharmaceutical Co Ltd | 954.14m | 166.44m | 3.73bn | 447.00 | 22.02 | 1.18 | -- | 3.91 | 1.06 | 1.06 | 6.05 | 19.78 | 0.2548 | 2.50 | 3.73 | 2,134,547.00 | 5.46 | 5.43 | 6.39 | 6.24 | 88.29 | 89.93 | 21.44 | 20.76 | 3.08 | -- | 0.0486 | 21.53 | 6.15 | -2.08 | 48.24 | -10.63 | 43.05 | -9.71 |
| Hunan Warrant Pharmaceutical Co Ltd | 1.45bn | 222.11m | 3.74bn | 1.16k | 16.86 | 2.10 | -- | 2.59 | 2.37 | 2.37 | 15.44 | 19.01 | 0.6713 | 1.50 | 8.93 | 1,246,491.00 | 9.31 | 11.21 | 11.21 | 14.05 | 64.09 | 69.00 | 13.88 | 13.96 | 3.02 | -- | 0.0252 | 8.05 | 10.84 | 18.50 | 15.60 | 19.02 | 24.49 | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.81bn | 94.97m | 3.79bn | 2.47k | 39.86 | 3.29 | -- | 2.09 | 0.2374 | 0.2374 | 4.52 | 2.87 | 0.6721 | 2.88 | 3.81 | 732,708.90 | 3.80 | 5.81 | 6.29 | 9.78 | 50.33 | 58.01 | 5.66 | 7.03 | 0.8245 | 7.04 | 0.5246 | 21.74 | 25.75 | 14.13 | 24.29 | 1.16 | 46.37 | -- |
| Sinotherapeutics Inc | 368.86m | 76.25m | 3.79bn | 260.00 | 49.71 | 3.16 | -- | 10.27 | 0.1682 | 0.1682 | 0.8137 | 2.65 | 0.275 | 3.08 | 5.83 | 1,418,710.00 | 5.69 | -- | 6.09 | -- | 51.77 | -- | 20.67 | -- | 9.09 | -- | 0.00006 | -- | 21.13 | -- | -34.29 | -- | -- | -- |
Data as of Jul 24 2024. Currency figures normalised to Tibet Weixinkang Medicine Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
1.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Essence Fund Co., Ltd.as of 31 Dec 2023 | 2.75m | 0.64% |
| Great Wall Fund Management Co., Ltd.as of 31 Dec 2023 | 1.20m | 0.28% |
| Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 500.00k | 0.12% |
| Nanhua Fund Management Co. Ltd.as of 31 Dec 2023 | 386.60k | 0.09% |
| Hongde Fund Management Co., Ltd.as of 31 Dec 2023 | 275.40k | 0.06% |
| Dongxing Asset Management Co. Ltd.as of 31 Dec 2023 | 270.80k | 0.06% |
| Acadian Asset Management LLCas of 31 May 2024 | 180.70k | 0.04% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 116.00k | 0.03% |
| Tebon Fund Management Co. Ltd.as of 31 Dec 2023 | 72.30k | 0.02% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 31 Dec 2023 | 69.50k | 0.02% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
